比美替尼，又称Mektovi和ARY-162，是Array Biopharma开发的用于治疗各种癌症的抗癌小分子。比美替尼是MEK的选择性抑制剂，是肿瘤促进MAPK途径的中心激酶。
![methyl 4-fluoro-5-((2-fluorophenyl)amino)-1H-benzo[d]imidazole-6-carboxylate](/static/img/pharmaceutical-intermediate/BINI-007.png)
methyl 4-fluoro-5-((2-fluorophenyl)amino)-1H-benzo[d]imidazole-6-carboxylate
![5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-N-(2-(vinyloxy)ethoxy)-1H-benzo[d]imidazole-6-carboxamide](https://file.bidepharm.com/static/upload/proimg/785/1415559-75-9.png)
[1] US7235537B2
[2] US8961970B2
[3] WO03077914A1
[4] WO2005023251A1
[5] WO2013142182A2
![methyl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate](https://file.bidepharm.com/static/upload/proimg/702/606143-48-0.png)
![methyl 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate](https://file.bidepharm.com/static/upload/proimg/702/1415559-93-1.png)
![5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid](https://file.bidepharm.com/static/upload/proimg/702/1415564-99-6.png)
